ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Stryker receives FDA clearance for Incompass Total Ankle System

Streamlining total ankle replacement with data-driven implants and surgical flexibility

Stryker (NYSE: SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/

Stryker's Incompass® Total Ankle System integrates the technologies of the Inbone® and Infinity® systems into a single, comprehensive solution.

Stryker's Incompass® Total Ankle System integrates the technologies of the Inbone® and Infinity® systems into a single, comprehensive solution.

“Incompass reflects our commitment to redefining what’s possible in total ankle replacement,” said Adam Jacobs, vice president and general manager of Stryker’s Foot & Ankle business. “By building on decades of clinical experience and leveraging extensive data insights, we’re setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.”

Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care.

Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company’s Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Copyright © 2025 Stryker

Content ID: FA-INCO-PRESS-2016296

References:

1. Based on internal data as of 5/1/2025.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.